Minerva Neurosciences, Inc. (NERV)
USD 2.19
(-5.6%)
USD 2.19
(-5.6%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.78 Million | -24.64 Million | -24.6 Million | -33.82 Million | -43.43 Million | -41.94 Million |
| Net Income | -30 Million | -32.1 Million | -49.9 Million | 1.94 Million | -72.18 Million | -50.17 Million |
| Depreciation & Amortization | 30.98 Thousand | 8513.00 | 101.78 Thousand | 176.17 Thousand | 161.5 Thousand | 17.46 Thousand |
| Deferred income taxes | -835.65 Million | -1.8 Billion | -1.8 Million | - | -2.25 Million | -119.61 Thousand |
| Stock-based compensation | 1.96 Million | 4.1 Million | 5.21 Million | 9.7 Million | 9.17 Million | 8.18 Million |
| Change in working capital | 4.93 Million | -4.06 Million | 259.33 Thousand | -45.55 Million | 3.43 Million | 110.96 Thousand |
| Other non-cash items | 843.93 Million | 1.81 Billion | 21.52 Million | -86.77 Thousand | 18.23 Million | 38.04 Thousand |
| Investing Cash Flow | - | -16.32 Thousand | - | 24.52 Million | 14.08 Million | 69.48 Million |
| Investments in PPE | 2.00 | -16.32 Thousand | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | -3.87 Million | -61.09 Million | -40.66 Million |
| Sales/Maturities of investments | - | - | - | 28.4 Million | 75.17 Million | 110.15 Million |
| Other Investing Activities | - | -16.32 Million | - | - | - | - |
| Financing Cash Flow | 19.6 Million | -5.00 | 60 Million | 13.23 Million | 524.99 Thousand | -3.34 Million |
| Debt repayment | - | - | - | - | - | -4 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 19.6 Million | - | - | 12.55 Million | 524.99 Thousand | 655.93 Thousand |
| Other Financing Activities | -396.29 Thousand | -5.00 | 60 Million | 687.98 Thousand | 524.99 Million | 655.93 Thousand |
| Accounts receivables | - | -3.11 Million | - | - | - | - |
| Accounts payables | 835.65 Thousand | -883.54 Thousand | 857.6 Thousand | -1.32 Million | 517.33 Thousand | 364.03 Thousand |
| Inventory | - | 3.11 Million | - | - | - | - |
| Other working capital | 4.1 Million | -3.17 Million | -598.26 Thousand | -44.23 Million | 2.91 Million | -253.07 Thousand |
| Cash at beginning of period | 36.19 Million | 60.85 Million | 25.45 Million | 21.51 Million | 50.33 Million | 26.13 Million |
| Cash at end of period | 41.01 Million | 36.19 Million | 60.85 Million | 25.45 Million | 21.51 Million | 50.33 Million |
| Capital Expenditure | 2.00 | -16.32 Thousand | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 4.81 Million | -24.66 Million | 35.39 Million | 3.94 Million | -28.82 Million | 24.2 Million |
| Free Cash Flow | -14.78 Million | -24.66 Million | -24.6 Million | -33.82 Million | -43.43 Million | -41.94 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 5710.92 Billion | -8.23 Million | -8.56 Million | -30 Million | -9.02 Million | -6.9 Million |
| Depreciation & Amortization | 4.08 Billion | 7746.00 | 7745.00 | 30.98 Thousand | 7746.00 | 7745.00 |
| Deferred income taxes | - | - | - | -835.65 Million | 7.82 Million | -7.82 Million |
| Stock-based compensation | 1075.87 Billion | 329.31 Thousand | 438.84 Thousand | 1.96 Million | 611.06 Thousand | 371.94 Thousand |
| Change in working capital | -1.42 Million | 1.64 Million | -222.3 Thousand | 4.93 Million | 222.11 Thousand | 549.78 Thousand |
| Other non-cash items | -21174.65 Billion | 3.26 Million | 3.07 Million | 843.93 Million | -5.63 Million | 6.9 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | 19.6 Million | 19.58 Billion | -86.69 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 19.6 Million | 19.99 Billion | -86.69 Thousand |
| Other Financing Activities | - | - | - | -396.29 Thousand | -415.89 Million | -86.69 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -1252.12 Billion | -607.22 Thousand | -369.75 Thousand | 835.65 Thousand | 410.25 Thousand | 1.09 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -2.4 Million | 2.25 Million | 147.44 Thousand | 4.1 Million | -188.13 Thousand | -547.03 Thousand |
| Cash at beginning of period | 30.98 Million | 34.91 Million | 41.01 Million | 36.19 Million | 47 Million | 51.89 Million |
| Cash at end of period | 26628.79 Billion | 30.98 Million | 34.91 Million | 41.01 Million | 41.01 Million | -6.9 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 26628.76 Billion | -3.93 Million | -6.09 Million | 4.81 Million | -5.99 Million | -58.79 Million |
| Free Cash Flow | -14383.77 Billion | -3.93 Million | -6.09 Million | -14.78 Million | -5.99 Million | -6.9 Million |
GBIO
GPTHEALTH
AGRO3
KOCMT
LOVABLE
UNITECH